2019 International Pharmaceutical Innovation Forum to Take Place in Beijing


 (BEIJING, 10 September 2018) Today, the R&D-based Pharmaceutical Association Committee  (RDPAC) announced that the 2019 International  Pharmaceutical Innovation Forum (IPIF19) will take place on 26 March 2019 in  Beijing, connecting global thought  leaders, policy makers, scientists, industry leaders, think tanks for a one-day  top content event. The forum is privileged to have some of the most  authoritative and influential speakers, some of whom are global transformers.


Building off the success of the first IPIF  in 2017, which saw the launch of the Coalition for Pharmaceutical Innovation, a  strategic platform to maintain regular communications with government and  industry stakeholders, the 2019 agenda is unprecedented, offering participants  a packed program of diverse topics to discuss the most exciting developments  and most pressing topics related to patient centric health, followed by an  award ceremony for the first-ever Prix Galien China recipients.


Today’s announcement took place at the 2018  Nobel Laureate Summit in Chengdu, which for five years has acted as a gathering  place for top health care and technology talent to meet and promote  collaboration across industries and sectors. IPIF19, like the Nobel Laureate Summit,  will serve as a platform of common dialogue among the various stakeholders in  health care, for whom collaboration will play an increasingly-important role in  benefitting patients. Topics discussed at IPIF19 will include using  pharmaceutical innovation as a vehicle to advance economic development and  broad social progress within China; examining opportunities for collaboration  both within the health care sector and across other sectors, such as  technology; policy and regulatory priorities for the coming years; and methods  for ensuring all efforts achieve the end goal of improving patient well-being.  Additionally, as the equivalent of the Nobel Prize for pharmaceutical  innovation, Prix  Galien China will help to showcase China’s growing role as an established  global player in health care innovation.


“Today’s pharmaceutical innovation  landscape is moving quickly, providing advances in treatment previously thought  impossible,” said Rogier Janssens, executive member of RDPAC.  “As China works to grow its global brand as a hub for scientific advancement,  as well as reap the economic and social benefits of a dynamic innovation  ecosystem, IPIF19 will provide an inclusive platform for high-level dialogue  about where we are headed next.”


RDPAC, which represents 40 member  companies in China that together invest approximately RMB 8 billion  annually into pharmaceutical R&D, is committed to building a healthy  China through innovation, according to Kang Wei, the organization’s managing director. In the 20 years since RDPAC was founded, the organization has  helped contribute to the development of China’s pharmaceutical industry through  continued investment that has helped bring roughly 80 percent of the innovative  drugs in China to the market.


“At our research and development centers  throughout China, thousands of researchers are working every day to find the  next wave of breakthrough treatments that will improve patient outcomes both in  China and around the world,” said Wei. “It is our honor to illuminate this stellar  work by hosting the first Prix Galien China, and we will take this opportunity  as our serious responsibility to showcase this country’s dynamic innovation  ecosystem.”


The Prix Galien China – which for the first  time in the 48-year history of the Prix Galien Foundation has included China as  one of the now-14 countries recognized in the pursuit of novel medicines and  treatments – will demonstrate China’s growing role as an established player in  health care innovation. Judged by a committee of internationally-recognized  scientists from industry,  academia, and development organizations in Europe, America, and China, the  awards will recognize outstanding contributions in three categories: digital  innovation, innovative products, and research. Among the judges will be Sue Desmond-Hellmann, Committee  Chair of the Prix Galien USA and CEO of the Bill & Melinda Gates  Foundation, which this year will act as the philanthropic partner for IPIF19,  recognizing China’s vital role in the organization’s mission to further global  public health. 


“I’m excited by this landmark partnership.  I love visiting China and every time I do, I’m amazed by the ever-growing  capacity for innovation, and ever-deepening pool of talented scientists and  technicians. We have big ambitions in global health and we need more  discoveries to further improve the human condition. IPIF19 will showcase  China’s potential in the field and encourage vital new medical breakthroughs.,”  said Desmond-Hellmann.


The  Pharmaceutical Research and Manufacturers of America (PhRMA) is a supporting  partner for IPIF19 and shares the goal of connecting Chinese and international  stakeholders from across health care and other sectors. “China is growing to  become a global hub for biopharmaceutical research and development, aided by  important policy reforms underway,” said PhRMA president and CEO Stephen J.  Ubl. “In today’s new era of medicine, international cooperation and  harmonization will continue to be foundational to success in delivering  life-saving treatments and cures to patients.”


More details about 2019 IPIF and Prix  Galien China please visit:  ipif.rdpac.org


About  RDPAC  

Under the China Association of Enterprises  with Foreign Investment (CAEFI), the R&D-based Pharmaceutical Association  Committee (RDPAC) is a non-profit organization made up of 38 member companies  with pharmaceutical R&D capability that together invest an annual total of  RMB9 billion into pharmaceutical innovation. Seventy percent of RDPAC members  have established manufacturing facilities in China summing up to 49 in total so  far, and 31 R&D centers were established by 17 companies. Holding the idea  of “Healthier China through Innovation”, RDPAC committed to be a valued partner  in delivering the “Healthy China 2030” goal to improve the health and quality  of life of people in China. RDPAC is member of International Federation of  Pharmaceutical Manufacturers & Associations (IFPMA). Learn more at http://www.rdpac.org/.


About  the Prix Galien Awards  

Created in France in 1970, the Prix Galien  Awards are the pharmaceutical industry’s equivalent of the Nobel Prize,  rewarding achievements in the development of novel medicines and medical  devices. As China has established itself as a critical player in pharmaceutical  innovation, the Galien Foundation has entrusted RDPAC to launch the Prix Galien  China for the first time in its history, as part of IPIF19.

Related articles: